Spectrum Sees Potential Path For Poziotinib In NSCLC Despite Expected CRL
The CRL follows a negative FDA advisory committee vote in September. The company will lay off three-quarters of its R&D force, but sees potential to partner or sell the asset.
You may also be interested in...
It remains unclear whether Rolvedon will achieve hoped-for sales milestones in a deal that Assertio said was part of a growth strategy emphasizing product and business acquisitions.
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
Biotech sponsors understandably discuss accelerated approval as an important consideration in development plans. But the head of the US FDA oncology program has a reminder for them: the pathway is intended to serve patients – not drug companies.